Inhibitors of DNA methylation: Beyond myelodysplastic syndromes

Nature Clinical Practice Oncology

Volumn 2, Issue SUPPL. 1, 2005, Pages

  Fenaux, Pierre ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Acute myeloid leukemia; Azacitidine; Chronic myeloid leukemia; Decitabine; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CREATININE; DNA METHYLTRANSFERASE INHIBITOR; ETANERCEPT; FR 901228; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; THALIDOMIDE; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMA; CPG ISLAND; DIARRHEA; DNA METHYLATION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DYSFUNCTION; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DNA MODIFICATION METHYLASES; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA;

EID: 31344475498     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0351     Document Type: Review

References (74)

1. Piskala A et al. (1964) Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine. Collect Czech Chem Commun 29: 2060-2076
2. Hanka LJ et al. (1966) Microbiological production of 5-azacytidine. I. Production and biological activity. Antimicrob Agents Chemother 6: 619-624
3. Silverman LR et al. (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (Suppl 1): 21-29
4. Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429-2440
5. Kornblith AB et al. (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 20: 2441-2452
6. Pharmion Corporation. (2004) Vidaza® (azacitidine, injectable, subcutaneous) package insert; Pharmion, Boulder, CO, USA.
7. Jones PA and Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21: 163-167
8. Behringer B et al. (2003) Prognosis of older patients with acute myeloid leukemia receiving either inducion or noncurative treatment: A single-center retrospective study. Ann Hematol 82: 381-389
9. Leith CP et al. (1997) Acute myeloid leukemia in the elderly: Assessment of multi-drug resistance (MDR) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standard chemotherapy: A Southwest oncology group study. Blood 89: 3323-3329
10. Stone RM et al. Acute myeloid leukemia. In American Society of Hematology Education Program Book. 2004 December 4-7; San Diego, 98-117 (Eds Broudy VC et al.) Washington, DC: American Society of Hematology
11. Deininger M et al. (2005) The develoment of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653
12. Hochhaus A et al. (2004) Clinical resistance to imatinib: Mechanisms and implications. Hematol Oncol Clin N Am 18: 641-656
13. Lee SJ et al. (1998) Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol 16: 2897-2903
14. Ghaddar HM et al. (1994) Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: Implications on the overlap between the two disease states. Leukemia 8: 1649-1653
15. Baylin SB and Herman JG (2000) DNA hypermethylation in tumorigenesis. Trends Genet 16: 168-174
16. Robertson KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20: 3139-3155
17. Costello JF and Plass C (2001) Methylation matters. J Med Genet 38: 285-303
18. Bestor T et al. (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203: 971-983
19. Okano M et al. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257
20. Issa J-P et al. (1997) DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 11 (Suppl 1): 7-11
21. Melki JR et al. (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59: 3730-3740
22. INK4B. Cancer Res 56: 722-777
23. Nguyen TT et al. (2000) Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: Biological implications. Blood 95: 2990-2992
24. Baylin SB et al. (1987) Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 70: 412-417
25. Malinen T et al. (1991) Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 77: 2435-2440
26. Roman-Gomez J et al. (2002) 5′ CpG Island hypermethylation is associated with transcription silencing of the p21 CIPI/WAFI/SDI1 gene and confers poor prognosis in acute lymphobalstic leukemia. Blood 99: 2291-2296
27. Christman JK (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495
28. Von Hoff DD and Slavik M (1977) 5-azacytidine - a new anticancer drug with significant activity in acute myeloblastic leukemia. Adv Pharmacol Chemother 14: 285-326
29. McCredie KB et al. (1973) Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemother Rep 57: 319-323
30. Tan C et al. (1973) Clinical trial of 5-azacytidine (5-azaCR) [abstract]. Cancer Res 14: 97
31. Karon M et al. (1973) 5-Azacytidine: A new active agent for the treatment of acute leukemia. Blood 42: 359-365
32. Von Hoff DD et al. (1976) 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85: 237-245
33. Vogler WR et al. (1976) 5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia. Blood 48: 331-337
34. Saiki JH et al. (1981) Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A Southwest Oncology Group Study. Cancer 47: 1739-1742
35. Case DC Jr (1982) 5-azacytidine in refractory acute leukemia. Oncology 39: 218-221
36. Winton EF et al. (1985) Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: A phase I-II trial of the Southeastern Cancer Study Group. Cancer Treat Rep 69: 807-811
37. Hakami N et al. (1987) Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 5: 1022-1025
38. Lee EJ et al. (1990) Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia 4: 835-838
39. Goldberg J et al. (1993) Mitoxantrone and 5-azacytidine for refractory/ relapsed ANLL or CML in blast crisis: A leukemia intergroup study. Am J Hematol 43: 286-290
40. Steuber CP et al. (1996) Induction treatment of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: A Pediatric Oncology Group randomized phase II study. J Clin Oncol 14: 1521-1525
41. Oblon D et al. (1984) Long-term follow up of brief, intensive chemotherapy without maintenance therapy for acute myelogenous leukemia (AML): A SECSG pilot study [abstract]. Proc Am Soc Clin Oncol 20: C-748
42. Grier HE et al. (1992) Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia 6 (Suppl 2): 48-51
43. Shadduck RK et al. (2004) AML induction therapy with outpatient azacitidine [abstract #1800]. In Meeting Abstracts of the American Society of Hematology: 2004 December 5; San Diego http://www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_4764] (accessed 28 September 2005);
44. also Blood 104 (Suppl 1): 499a
45. Schiffer CA et al. (1982) Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Cancer Treat Rep 66: 267-271
46. Dutcher JP et al. (1992) Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Leukemia 6: 770-775
47. Rivard GE et al. (1981) Phase I study on 5-Aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res 5: 453-462
48. Momparler RL et al. (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30: 277-286
49. Richel DJ et al. (1991) The antileukemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 64: 144-148
50. Petti AC et al. (1993) Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results. Leukemia 7 (Suppl 1): 36-41
51. Schwartsmann G et al. (1997) Decitabine (5-Aza-2-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations. Leukemia 11 (Suppl 1): 28-31
52. Willemze R et al. (1997) A randomized phase II study on the effects of 5-aza-2′ deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 11 (Suppl 1): 24-27
53. Kantarjian HM et al. (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11: 1617-1620
54. Sacchi S et al. (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86: 2632-2641
55. Wijermans P et al. (2000) Low-dose 5-aza-2′ deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multi-center phase II study in elderly patients. J Clin Oncol 18: 956-962
56. Issa JJ et al. (2004) Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′ deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640
57. Kantarjian HM et al. (2003) Results of decitabine (5-aza-2′ deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98: 522-528
58. de Lima M et al. (2003) Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97: 1242-1247
59. Ravandi F et al. (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: Results of a phase I study. Bone Marrow Transplant 27: 1221-1225
60. Kritz AD et al. (1996) Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Am J Hematol 5: 117-121
61. Camacho LH et al. (2001) Transcription modulation: A pilot study of sodium phenylbutyrate plus 5-azacytidine [abstract]. Blood 98: 460a
62. Miller CB et al. (2001) A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies [abstract]. Blood 98: 622a
63. Silverman LR et al. (1994) Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921 [abstract]. Am Hematol 68: A12
64. Kaminskas E et al. (2005) Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604-3608
65. Jaffe ES et al. (2001) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press
66. Momparler RL et al. (1997) Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 11: 175-180
67. Estey E et al. (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 15: 2969-2977
68. Rossi G et al. (2000) Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 14: 636-641
69. Parker JE et al. (2000) The role of apoptosis, proliferation, and the Bcl-2 related proteins in myelodysplastic syndromes and acute myeloid leukemias secondary to MDS. Blood 96: 3932-3938
70. Vardiman JW et al. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302
71. Claus R et al. (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22: 6489-6496
72. Chen RZ et al. (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395: 89-93
73. Sato N et al. (2003) Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95: 327-330
74. Eden A et al. (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455